MedTrace Logo

Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment

NCT07398001 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1042

Last updated 2026-02-09

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon.

The main questions it aims to answer are:

Does stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment?

Researchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up.

Participants will:

Be randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time

Conditions

  • Percutaneous Coronary Intervention
  • Antiplatelet Therapy
  • Drug-coated Balloon

Interventions

DRUG

Stop Antiplatelet

Antiplatelet discontinuation after DCB treatment

DRUG

Continue Antiplatelet

Antiplatelet continuation after DCB treatment

Sponsors & Collaborators

  • Ulsan University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2028-02-11
Completion
2030-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07398001 on ClinicalTrials.gov